GlassScriptPhysician profile
Michael W Nichols
NPI 1326020777
$3,683.12
in general payments reported to CMS, 2019-2025
31 companies · $707 in 2025
The $707 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $516 · 2022: $173 · 2023: $570 · 2024: $805 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $855.02 | 2019-2025 | |
| Novo Nordisk INC | $623.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $367.94 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $244.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $201.24 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $196.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $188.92 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.34 | 2019-2024 | Ofev, Jardiance |
| Amarin Pharma, INC. | $117.38 | 2019-2020 | |
| Exact Sciences Corporation | $103.30 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $75.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.64 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $61.03 | 2019-2025 | |
| Abbott Laboratories | $57.94 | 2024-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $41.18 | 2024 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $38.78 | 2025 | Fluad, Flucelvax |
| Genentech USA, INC. | $25.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.96 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.11 | 2024 | |
| Axsome Therapeutics, INC. | $22.03 | 2025 | Symbravo |
| Ibsa Pharma INC. | $20.66 | 2025 | Tirosint, Flector, Licart |
| Kaleo, INC. | $19.39 | 2023 | Auvi-Q |
| Pacira Therapeutics, INC. | $18.75 | 2019 | |
| Metuchen Pharmaceuticals | $17.91 | 2020 | |
| Astellas Pharma US INC | $17.56 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $16.78 | 2025 | Keveyis |
| Currax Pharmaceuticals LLC | $14.10 | 2020 | |
| Bausch Health US, LLC | $13.94 | 2019 | |
| Tolmar, INC. | $13.84 | 2024 | |
| Allergan, INC. | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.